- Trials with a EudraCT protocol (63)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
63 result(s) found for: Bowel obstruction.
Displaying page 1 of 4.
EudraCT Number: 2009-012981-30 | Sponsor Protocol Number: AGO/2009/005 | Start Date*: 2009-08-18 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstruction | |||||||||||||
Medical condition: Inoperable malignant bowel obstruction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002174-43 | Sponsor Protocol Number: A-48-52030-269 | Start Date*: 2014-03-27 | |||||||||||
Sponsor Name:IPSEN NV | |||||||||||||
Full Title: AN INTERNATIONAL, MULTICENTRIC, PROSPECTIVE, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG ASSOCIATED TO STANDARD OF CARE IN THE TREATMENT OF CLINICAL SYMPTOMS AS... | |||||||||||||
Medical condition: Inoperable malignant intestinal obstruction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002349-38 | Sponsor Protocol Number: 2-54-52030-156 | Start Date*: 2007-02-26 |
Sponsor Name:Beaufour Ipsen Pharma-Ipsen Biotech Department | ||
Full Title: Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with... | ||
Medical condition: Patient having a high digestive obstruction of malignant origin i.e. located on the upper part of the gastro-intestinal tract (stomach, duodenum, small bowel) for whom surgery is inappropriate. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003176-12 | Sponsor Protocol Number: A-93-52030-279 | Start Date*: 2014-08-27 | |||||||||||
Sponsor Name:IPSEN S.p.A | |||||||||||||
Full Title: A PHASE II, MULTICENTRE, RANDOMIZED CONTROLLED STUDY EVALUATING THE QUALITY OF LIFE IN PATIENTS WITH INOPERABLE MALIGNANT BOWEL OBSTRUCTION TREATED WITH LANREOTIDE AUTOGEL 120 MG IN COMBINATION WIT... | |||||||||||||
Medical condition: Inoperable malignant bowel obstruction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002685-38 | Sponsor Protocol Number: 2-2 | Start Date*: 2005-08-05 |
Sponsor Name:Yakult Honsha Co | ||
Full Title: Randomised controlled trial of metronidazole and probiotic preparation versus placebo in the treatment of irritable bowel syndrome | ||
Medical condition: Irritable Bowel Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005129-99 | Sponsor Protocol Number: TA799-013 | Start Date*: 2021-02-10 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: A multicenter, open-label, metabolic balance study to evaluate the effects of apraglutide on intestinal absorption in adult subjects with short bowel syndrome, intestinal failure (SBS-IF), and colo... | |||||||||||||
Medical condition: short bowel syndrome, intestinal failure (SBS-IF), colon-in-continuity (CIC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000854-24 | Sponsor Protocol Number: VE-CIP2001/2021 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:ALFASIGMA S.P.A. | |||||||||||||
Full Title: Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. | |||||||||||||
Medical condition: Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture si... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002586-34 | Sponsor Protocol Number: STEROID_MC_1 | Start Date*: 2020-11-12 | |||||||||||||||||||||||||||||||
Sponsor Name:Department of Anesthesiology, Copenhagen University Hospital Hvidovre, Capital Region of Denmark | |||||||||||||||||||||||||||||||||
Full Title: The effects of preoperative high-dose Dexamethasone on inflammatory response and recovery after emergency laparotomy, a randomized, double-blind, placebo-controlled clinical trial - AHA STEROID ... | |||||||||||||||||||||||||||||||||
Medical condition: Patients undergoing emergency laparotomy due to either Intestinal obstruction or perforated abdominal viscus. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023229-38 | Sponsor Protocol Number: TZP-101-CL-P008 | Start Date*: 2011-04-21 | |||||||||||
Sponsor Name:Tranzyme, Inc | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastroin... | |||||||||||||
Medical condition: post-operative ileus in subjects who have undergone partial bowel resection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) CZ (Completed) ES (Ongoing) BG (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001050-41 | Sponsor Protocol Number: RP1202 | Start Date*: 2015-06-12 | |||||||||||
Sponsor Name:Robarts Clinical Trials | |||||||||||||
Full Title: A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001248-23 | Sponsor Protocol Number: 12-CCEE | Start Date*: 2014-07-02 | ||||||||||||||||||||||||||
Sponsor Name:All Ireland Cooperative Oncology Research Group | ||||||||||||||||||||||||||||
Full Title: Treatment of Inoperable Colorectal Cancer with Electrochemotherapy through an Endoscopic System | ||||||||||||||||||||||||||||
Medical condition: Colorectal cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002773-38 | Sponsor Protocol Number: AIO-KRK-0214 | Start Date*: 2016-12-20 | |||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||
Full Title: mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial | |||||||||||||||||||||||
Medical condition: Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001234-17 | Sponsor Protocol Number: A3191084 | Start Date*: 2006-06-15 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in su... | |||||||||||||
Medical condition: Treatment of osteoarthritis (OA) and/or rheumatoid arthritis (RA) in high GI risk patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) BE (Completed) SE (Completed) CZ (Completed) LT (Completed) DE (Suspended by CA) EE (Completed) PT (Completed) GR (Completed) IE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004618-93 | Sponsor Protocol Number: R120502 | Start Date*: 2017-12-12 | ||||||||||||||||
Sponsor Name:University of Manchester | ||||||||||||||||||
Full Title: Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer | ||||||||||||||||||
Medical condition: Platinum-Resistant Ovarian Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000473-39 | Sponsor Protocol Number: CIR-ILI-2014 | Start Date*: 2015-01-19 | |||||||||||
Sponsor Name:Fundacio Parc Taulí | |||||||||||||
Full Title: Randomized and prospective clinical trial about the therapeutic use of diatrizoic acid (Gastrografin®) in postoperative ileus. | |||||||||||||
Medical condition: Postoperative paralytic Ileus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005421-30 | Sponsor Protocol Number: 07-IN-NX003 | Start Date*: 2008-04-17 |
Sponsor Name:Nektar Therapeutics | ||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients with Opioid-Induced Constipat... | ||
Medical condition: Opioid induced constipation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002087-10 | Sponsor Protocol Number: 1062.7 | Start Date*: 2007-08-28 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A randomised, double -blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops 10 mg administere... | |||||||||||||
Medical condition: To compare the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops to placebo in patients with functional constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002145-21 | Sponsor Protocol Number: 2007003 | Start Date*: 2007-12-21 | |||||||||||
Sponsor Name:Procter & Gamble Pharmaceuticals | |||||||||||||
Full Title: A Phase II, Randomized, Placebo-controlled Study of ATI-7505 in Patients with Chronic Idiopathic Constipation | |||||||||||||
Medical condition: Chronic Idiopathic Constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022810-26 | Sponsor Protocol Number: PERCAT01 Version 10, 31.01.2011 | Start Date*: 2011-03-16 | |||||||||||||||||||||
Sponsor Name:University Witten/Herdecke | |||||||||||||||||||||||
Full Title: MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CH... | |||||||||||||||||||||||
Medical condition: PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003279-38 | Sponsor Protocol Number: TZP-101-CL-G004 | Start Date*: 2007-08-17 |
Sponsor Name:Tranzyme Inc. | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe G... | ||
Medical condition: TZP-101 will be developed as a first-in class therapy for the treatment of gastric dysmotility. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
